Олександр Миколайович Семенов
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Олександр Миколайович Семенов has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
О. М. Заліська
5 shared publications- Olha Zaliska
SNE «Danylo Halytsky Lviv National Medical University», Lviv, Ukraine
3 shared publications - Z. O. Zabolotnya
Danylo Halytsky Lviv National Medical University
3 shared publications - B. M. Zalisky
State nonprofit company «Danylo Halytsky Lviv National Medical University», Lviv, Ukraine
2 shared publications - I. H. Mudrak
National Pirogov Memorial Medical University
2 shared publications Н. М. Максимович
2 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 111 (1) , 89-94
The study of the domestic market of antiviral drugs for the pharmacotherapy of complicated influenza in Ukraine
Aim. To study the domestic market of antiviral drugs – neuraminidase inhibitors, which are recommended by the clinical treatment protocols for the pharmacotherapy of patients with complicated forms of influenza; to determine their cost aspects and accessibility for the patient. Materials and methods. The normative and legislative acts and sources of scientific literature on the pharmaceutical component of the treatment of complicated forms of influenza using antiviral drugs, neuraminidase inhibitors (ATC code J05A H), in Ukraine were reviewed. The pharmaceutical market of Ukraine was analyzed in terms of the availability and accessibility of this group of drugs to the population. Results. Among acute respiratory viral infections, influenza is a key disease among the population in terms of the number of reported cases, severe complications and disability. Severe forms of influenza require inpatient treatment of patients using antiviral drugs. According to the clinical treatment protocol and the WHO recommendations, it is recommended to use neuraminidase inhibitors (J05A H), including Oseltamivir, Zanamivir, Laninavir and Piramivir with the activity against various strains of the influenza virus, for the pharmacotherapy of complicated forms of influenza. Neuraminidase inhibitors are represented in the domestic pharmaceutical market of Ukraine by 15 trade names of foreign manufacturers, which indicates complete import dependence and requires the development and introduction of domestic antiviral drugs into production. Conclusions. Severe forms of influenza can lead to significant complications of the patient’s disease, and, therefore, the use of neuraminidase inhibitors should prevent the occurrence of severe pathological changes in the patient’s body. The most affordable drug for the patient is Oseltamivir, 75 mg, No. 10 manufactured by Strides India, the course of treatment for which in 2026 will be 5 % of the patient’s minimum wage.
- 31 March 2026
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 111 (1) , 89-94
Open AccessThe study of the domestic market of antiviral drugs for the pharmacotherapy of complicated influenza in Ukraine
Aim. To study the domestic market of antiviral drugs – neuraminidase inhibitors, which are recommended by the clinical treatment protocols for the pharmacotherapy of patients with complicated forms of influenza; to determine their cost aspects and accessibility for the patient. Materials and methods. The normative and legislative acts and sources of scientific literature on the pharmaceutical component of the treatment of complicated forms of influenza using antiviral drugs, neuraminidase inhibitors (ATC code J05A H), in Ukraine were reviewed. The pharmaceutical market of Ukraine was analyzed in terms of the availability and accessibility of this group of drugs to the population. Results. Among acute respiratory viral infections, influenza is a key disease among the population in terms of the number of reported cases, severe complications and disability. Severe forms of influenza require inpatient treatment of patients using antiviral drugs. According to the clinical treatment protocol and the WHO recommendations, it is recommended to use neuraminidase inhibitors (J05A H), including Oseltamivir, Zanamivir, Laninavir and Piramivir with the activity against various strains of the influenza virus, for the pharmacotherapy of complicated forms of influenza. Neuraminidase inhibitors are represented in the domestic pharmaceutical market of Ukraine by 15 trade names of foreign manufacturers, which indicates complete import dependence and requires the development and introduction of domestic antiviral drugs into production. Conclusions. Severe forms of influenza can lead to significant complications of the patient’s disease, and, therefore, the use of neuraminidase inhibitors should prevent the occurrence of severe pathological changes in the patient’s body. The most affordable drug for the patient is Oseltamivir, 75 mg, No. 10 manufactured by Strides India, the course of treatment for which in 2026 will be 5 % of the patient’s minimum wage.
- Open Access
- 27 February 2026
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 1,p. 12-22
Study on the problems and implementation of vaccination in pharmacies according to the results of a survey of pharmacists in Ukraine and the prospects of their continuous professional development
Pharmacies, as health care institutions, could be involved in carrying out preventive vaccination measures to prevent influenza and new strains of COVID-19 with information support for pharmacy professionals, patients amd material base of pharmacies. Since after the pandemic in some EU countries vaccination is carried out in pharmacies. The aim study was to systematize the results of the experience of EU countries on vaccination issue against influenza and COVID-19 in pharmacies and the new roles of pharmacists; to study the awareness of pharmacists on vaccination in pharmacies, to identify areas for training in continuous professional development; to identify problematic aspects for vaccination implementation in pharmacies of Ukraine. Data from international literature on the implementation of population vaccination in pharmacies in EU countries and the new roles of a pharmacist were summarized and systematized. A study of pharmacists' awareness of the introduction of vaccination in pharmacies was conducted, a special survey was developed using Google form and was conducted for 205 managers and pharmacists from September 2025 to January 2026. Methods: systematization and generalization, content analysis of literature data, questionnaires, surveys, descriptive statistics methods. Systematization of literature data showed that vaccination against influenza and COVID-19 is effective, especially for risk groups. It was established that in some EU countries specially trained pharmacists have the right to conduct vaccination against influenza and COVID-19 in a pharmacy, provide pharmaceutical care on all issues of immunization. In Ukraine, after the COVID-19 pandemic, relevant legislative changes provided the possibility of conducting vaccination in a pharmacy subject to compliance with certain licensing requirements. The results of the survey showed that only 29.5% of pharmacists consider themselves prepared to conduct vaccination in a pharmacy, but the majority, 70.5%, indicate that they need thorough training, new cycles of postgraduate education in order to provide informational care to patients about the need for vaccination, selection of vaccines, taking into account data on age, gender, concomitant chronic diseases, the likelihood of adverse reactions, and vaccination timetable. Problematic aspects related to the material base of pharmacies, awareness of pharmacists, and the population regarding the introduction of vaccination in pharmacies in Ukraine were identified. Systematic measures are needed to educate pharmacists about vaccination, and to introduce reimbursement for influenza vaccines for at-risk groups, in particular for doctors and pharmacists.
- 27 February 2026
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 1,p. 12-22
Open AccessStudy on the problems and implementation of vaccination in pharmacies according to the results of a survey of pharmacists in Ukraine and the prospects of their continuous professional development
Pharmacies, as health care institutions, could be involved in carrying out preventive vaccination measures to prevent influenza and new strains of COVID-19 with information support for pharmacy professionals, patients amd material base of pharmacies. Since after the pandemic in some EU countries vaccination is carried out in pharmacies. The aim study was to systematize the results of the experience of EU countries on vaccination issue against influenza and COVID-19 in pharmacies and the new roles of pharmacists; to study the awareness of pharmacists on vaccination in pharmacies, to identify areas for training in continuous professional development; to identify problematic aspects for vaccination implementation in pharmacies of Ukraine. Data from international literature on the implementation of population vaccination in pharmacies in EU countries and the new roles of a pharmacist were summarized and systematized. A study of pharmacists' awareness of the introduction of vaccination in pharmacies was conducted, a special survey was developed using Google form and was conducted for 205 managers and pharmacists from September 2025 to January 2026. Methods: systematization and generalization, content analysis of literature data, questionnaires, surveys, descriptive statistics methods. Systematization of literature data showed that vaccination against influenza and COVID-19 is effective, especially for risk groups. It was established that in some EU countries specially trained pharmacists have the right to conduct vaccination against influenza and COVID-19 in a pharmacy, provide pharmaceutical care on all issues of immunization. In Ukraine, after the COVID-19 pandemic, relevant legislative changes provided the possibility of conducting vaccination in a pharmacy subject to compliance with certain licensing requirements. The results of the survey showed that only 29.5% of pharmacists consider themselves prepared to conduct vaccination in a pharmacy, but the majority, 70.5%, indicate that they need thorough training, new cycles of postgraduate education in order to provide informational care to patients about the need for vaccination, selection of vaccines, taking into account data on age, gender, concomitant chronic diseases, the likelihood of adverse reactions, and vaccination timetable. Problematic aspects related to the material base of pharmacies, awareness of pharmacists, and the population regarding the introduction of vaccination in pharmacies in Ukraine were identified. Systematic measures are needed to educate pharmacists about vaccination, and to introduce reimbursement for influenza vaccines for at-risk groups, in particular for doctors and pharmacists.
- Open Access
- 17 October 2025
- Published by Publishing House Helvetica (Publications) in Health & Education
- No. 3,p. 151-158
РОЗШИРЕННЯ РОЛЕЙ ТА ФУНКЦІЙ ФАРМАЦЕВТИЧНИХ ПРАЦІВНИКІВ ВНАСЛІДОК ПАНДЕМІЇ КОРОНАВІРУСНОЇ ХВОРОБИ (COVID-19) В УКРАЇНІ
Коронавірусна хвороба (COVID-19) – важке мультисистемне вірусне захворювання з великою кількістю симптомів і ймовірністю виникнення важких ускладнень, які значно погіршують якість життя пацієнтів.У 2020 році COVID-19 була проголошена пандемією з уведенням значних карантинних обмежень для громадян багатьох країн. І хоча у травні 2023 року Всесвітня організація охорони здоров’я припинила дію пандемічних заходів, за хворобою зберігається статус небезпечного та соціально значущого захворювання.Під час пандемії COVID-19 аптеки стали одним із ключових об’єктів з надання первинної медико-фармацевтичної і профілактичної допомоги населенню за кількістю консультацій відвідувачів аптек і фармацевтичної допомоги хворим із неускладненими формами COVID-19, що спричинило виникнення нових і розширення існуючих функцій у професійній діяльності фармацевтів аптек та клінічних фармацевтів, зменшило навантаження на медичних працівників у системі охорони здоров’я країни.COVID-19, як нове маловивчене захворювання, та велика кількість хворих на початку пандемії спричинили значне навантаження на фармацевтів аптек і клінічних фармацевтів, що значно збільшила обсяг їхніх компетентностей та зумовило появу нових професійних обов’язків.Під час пандемії COVID-19 професійні обов’язки фармацевтів аптеки та клінічних фармацевтів змінювались відповідно до епідеміологічної ситуації в регіоні, щільності навантаження хворих на лікувальний заклад чи аптеку, та вдосконалення методів лікування, профілактичних заходів і реабілітації після перенесеного захворювання.Висновки. Роль як фармацевтів аптек, так і клінічних фармацевтів у наданні допомоги хворим із COVID-19 багатогранна й складається не лише із забезпечення пацієнтів лікарськими засобами, медичними виробами та вироблення у хворих прихильності до лікування, але й в інформуванні медичних працівників щодо інноваційних лікарських засобів для лікування COVID-19, можливих негативних наслідків фармакотерапії, небажаних взаємодій між ліками та виникнення поліпрагмазії.
- 17 October 2025
- Published by Publishing House Helvetica (Publications) in Health & Education
- No. 3,p. 151-158
Open AccessРОЗШИРЕННЯ РОЛЕЙ ТА ФУНКЦІЙ ФАРМАЦЕВТИЧНИХ ПРАЦІВНИКІВ ВНАСЛІДОК ПАНДЕМІЇ КОРОНАВІРУСНОЇ ХВОРОБИ (COVID-19) В УКРАЇНІ
Коронавірусна хвороба (COVID-19) – важке мультисистемне вірусне захворювання з великою кількістю симптомів і ймовірністю виникнення важких ускладнень, які значно погіршують якість життя пацієнтів.У 2020 році COVID-19 була проголошена пандемією з уведенням значних карантинних обмежень для громадян багатьох країн. І хоча у травні 2023 року Всесвітня організація охорони здоров’я припинила дію пандемічних заходів, за хворобою зберігається статус небезпечного та соціально значущого захворювання.Під час пандемії COVID-19 аптеки стали одним із ключових об’єктів з надання первинної медико-фармацевтичної і профілактичної допомоги населенню за кількістю консультацій відвідувачів аптек і фармацевтичної допомоги хворим із неускладненими формами COVID-19, що спричинило виникнення нових і розширення існуючих функцій у професійній діяльності фармацевтів аптек та клінічних фармацевтів, зменшило навантаження на медичних працівників у системі охорони здоров’я країни.COVID-19, як нове маловивчене захворювання, та велика кількість хворих на початку пандемії спричинили значне навантаження на фармацевтів аптек і клінічних фармацевтів, що значно збільшила обсяг їхніх компетентностей та зумовило появу нових професійних обов’язків.Під час пандемії COVID-19 професійні обов’язки фармацевтів аптеки та клінічних фармацевтів змінювались відповідно до епідеміологічної ситуації в регіоні, щільності навантаження хворих на лікувальний заклад чи аптеку, та вдосконалення методів лікування, профілактичних заходів і реабілітації після перенесеного захворювання.Висновки. Роль як фармацевтів аптек, так і клінічних фармацевтів у наданні допомоги хворим із COVID-19 багатогранна й складається не лише із забезпечення пацієнтів лікарськими засобами, медичними виробами та вироблення у хворих прихильності до лікування, але й в інформуванні медичних працівників щодо інноваційних лікарських засобів для лікування COVID-19, можливих негативних наслідків фармакотерапії, небажаних взаємодій між ліками та виникнення поліпрагмазії.
- Open Access
- 1 July 2025
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 11 (2) , 73-78
Assessment of cost aspects of prevention of excessive thromboformation in patients with COVID-19 in Ukraine
COVID-19 is a multisymptomatic infectious viral disease, one of the main complications of which is excessive blood clot formation, which can lead to myocardial infarction and stroke. The aim of the study was to assess the cost aspects of market offers of medicines recommended for the prevention of excessive thrombosis in patients who have had COVID-19 and are prone to thrombosis. Materials and methods. To conduct the study, data from the State Register of Medicines of Ukraine, Compendium, and the Register of Wholesale Prices for Medicines. The data of the Protocol "Provision of medical care for the treatment of coronavirus disease (COVID-19)" has been systematized and summarized. Additionally, international recommendations for providing care to patients with COVID-19 were studied through Embase Global Health, Medline, PubMed. The following methods were used: systematic review, documentary, bibliographic, statistical, analytical, comparative, generalizing, informational. Results. In Ukraine, the protocol "Providing medical care for the treatment of coronavirus disease (COVID-19)" is in effect, which recommends that after COVID-19, patients with a risk of excessive thromboembolism continue anticoagulant therapy with oral anticoagulants, which include direct thrombin inhibitors (Dabigatran) and direct factor Xa inhibitors (Rivaroxaban, Apixaban). As a result of the conducted studies, it was found that the cost of a 30-day course of preventive treatment for a patient is: apixaban 2.5 mg - 1398.00 UAH; pradakasa 300 mg - 1523.40 UAH; xarelto 15 mg/20 mg - 1871.94 UAH. The cost of pharmacotherapy with apixaban 2.5 mg is the lowest compared to xarelto by 1.3 times. Conclusions. Prophylactic pharmacotherapy with oral anticoagulants for patients at risk of excessive thromboembolism after COVID-19 should lead to normalization of blood coagulation status and prevent thromboembolism
- 1 July 2025
- Published by National University of Pharmacy in Social Pharmacy in Health Care
- Vol. 11 (2) , 73-78
Open AccessAssessment of cost aspects of prevention of excessive thromboformation in patients with COVID-19 in Ukraine
COVID-19 is a multisymptomatic infectious viral disease, one of the main complications of which is excessive blood clot formation, which can lead to myocardial infarction and stroke. The aim of the study was to assess the cost aspects of market offers of medicines recommended for the prevention of excessive thrombosis in patients who have had COVID-19 and are prone to thrombosis. Materials and methods. To conduct the study, data from the State Register of Medicines of Ukraine, Compendium, and the Register of Wholesale Prices for Medicines. The data of the Protocol "Provision of medical care for the treatment of coronavirus disease (COVID-19)" has been systematized and summarized. Additionally, international recommendations for providing care to patients with COVID-19 were studied through Embase Global Health, Medline, PubMed. The following methods were used: systematic review, documentary, bibliographic, statistical, analytical, comparative, generalizing, informational. Results. In Ukraine, the protocol "Providing medical care for the treatment of coronavirus disease (COVID-19)" is in effect, which recommends that after COVID-19, patients with a risk of excessive thromboembolism continue anticoagulant therapy with oral anticoagulants, which include direct thrombin inhibitors (Dabigatran) and direct factor Xa inhibitors (Rivaroxaban, Apixaban). As a result of the conducted studies, it was found that the cost of a 30-day course of preventive treatment for a patient is: apixaban 2.5 mg - 1398.00 UAH; pradakasa 300 mg - 1523.40 UAH; xarelto 15 mg/20 mg - 1871.94 UAH. The cost of pharmacotherapy with apixaban 2.5 mg is the lowest compared to xarelto by 1.3 times. Conclusions. Prophylactic pharmacotherapy with oral anticoagulants for patients at risk of excessive thromboembolism after COVID-19 should lead to normalization of blood coagulation status and prevent thromboembolism
- Open Access
- 30 June 2025
- Published by Publishing House Helvetica (Publications) in Health & Education
- No. 2,p. 132-136
ІНФОРМАЦІЙНЕ ЗАБЕЗПЕЧЕННЯ ФАХІВЦІВ ФАРМАЦІЇ ЩОДО ПОСТКОВІДНОГО СИНДРОМУ
Коронавірусна хвороба (COVID-19) – гостре респіраторне вірусне захворювання, яке характеризується ураженням багатьох органів і, як наслідок, великою кількістю симптомів у пацієнтів. Після перенесення гострої фази захворювання у 10 % хворих один або декілька симптомів можуть зберігатися тривалий проміжок часу, що значно погіршує їхній фізичний та емоційний стан. Даний хронічний системний хворобливий стан отримав назву постковідного синдрому. Пацієнти з ознаками постковідного синдрому не завжди пов’язують патологічні зміни у своєму організмі з перенесеним COVID-19 і можуть звернутися за фармацевтичною допомогою до фармацевтичного працівника, пов’язуючи свій стан з іншими подібними за симптоматикою захворюваннями. Тому для надання повноцінної фахової фармацевтичної допомоги фармацевт має чітко знати симптоматику, методи діагностики, лікування та реабілітації пацієнтів з ознаками постковідного синдрому.Аптека як заклад охорони здоров’я, особливо в умовах воєнного стану, може виконувати функції формування у пацієнтів, які перенесли COVID-19 та мають ознаки постковідного синдрому, алгоритму відновлення після гострої стадії захворювання. І тому дуже важливою є поінформованість фахівців фармації, які надають фармацевтичну допомогу хворим із симптомами постковідного синдрому щодо лікарських засобів за даними доказової медицини про їх ефективність та безпеку.Із метою покращення знань фахівців фармації щодо постковідного синдрому для надання якісної фармацевтичної допомоги пацієнтам із постковідним синдромом нами узагальнено дані літератури щодо патологічних змін в організмі людини після ураження SARS-CoV-2, методи відновлювальної фармакотерапії та заходи реабілітації.Постковідний синдром проявляється у пацієнтів різноманітними симптомами та станами, включаючи мультисистемний запальний синдром, задишку та біль у грудях, кашель, постуральну ортостатичну тахікардію, втому за фізичного навантаження або без нього, м’язову слабкість, міалгію, когнітивні порушення та ін.Симптоми постковідного синдрому поділяють на постійні та періодичні. У пацієнта може спостерігатись один або декілька симптомів одночасно. Пацієнти, які були госпіталізовані в інфекційні відділення лікувальних закладів для лікування гострої фази захворювання на COVID-19, мають більшу ймовірність тривалого перебігу захворювання та важкого постковідного синдрому у вигляді різноманітних патологічних проявів, що вказує на ураження багатьох систем та органів.На сучасному етапі фахівцю фармації потрібно добре знати і орієнтуватися не лише в основних симптомах та лікуванні гострої фази COVID-19, а й володіти знаннями щодо негативних наслідків даного захворювання для організму пацієнта у вигляді постковідного синдрому, методів діагностики, фармакотерапії та видів реабілітаційних заходів. Коронавірусна хвороба (COVID-19) та постковідні стани є важким мультисистемним вірусним захворюванням із важкими довготривалими наслідками для організму хворого, які пацієнт не завжди пов’язує з перенесеним захворюванням, і тому фахівці фармації як найдоступніші для населення медичні працівники мають володіти знаннями щодо основних симптомів, діагностики та лікування COVID-19 та постковідного синдрому для надання повноцінної та якісної фармацевтичної допомоги...
- 30 June 2025
- Published by Publishing House Helvetica (Publications) in Health & Education
- No. 2,p. 132-136
Open AccessІНФОРМАЦІЙНЕ ЗАБЕЗПЕЧЕННЯ ФАХІВЦІВ ФАРМАЦІЇ ЩОДО ПОСТКОВІДНОГО СИНДРОМУ
Коронавірусна хвороба (COVID-19) – гостре респіраторне вірусне захворювання, яке характеризується ураженням багатьох органів і, як наслідок, великою кількістю симптомів у пацієнтів. Після перенесення гострої фази захворювання у 10 % хворих один або декілька симптомів можуть зберігатися тривалий проміжок часу, що значно погіршує їхній фізичний та емоційний стан. Даний хронічний системний хворобливий стан отримав назву постковідного синдрому. Пацієнти з ознаками постковідного синдрому не завжди пов’язують патологічні зміни у своєму організмі з перенесеним COVID-19 і можуть звернутися за фармацевтичною допомогою до фармацевтичного працівника, пов’язуючи свій стан з іншими подібними за симптоматикою захворюваннями. Тому для надання повноцінної фахової фармацевтичної допомоги фармацевт має чітко знати симптоматику, методи діагностики, лікування та реабілітації пацієнтів з ознаками постковідного синдрому.Аптека як заклад охорони здоров’я, особливо в умовах воєнного стану, може виконувати функції формування у пацієнтів, які перенесли COVID-19 та мають ознаки постковідного синдрому, алгоритму відновлення після гострої стадії захворювання. І тому дуже важливою є поінформованість фахівців фармації, які надають фармацевтичну допомогу хворим із симптомами постковідного синдрому щодо лікарських засобів за даними доказової медицини про їх ефективність та безпеку.Із метою покращення знань фахівців фармації щодо постковідного синдрому для надання якісної фармацевтичної допомоги пацієнтам із постковідним синдромом нами узагальнено дані літератури щодо патологічних змін в організмі людини після ураження SARS-CoV-2, методи відновлювальної фармакотерапії та заходи реабілітації.Постковідний синдром проявляється у пацієнтів різноманітними симптомами та станами, включаючи мультисистемний запальний синдром, задишку та біль у грудях, кашель, постуральну ортостатичну тахікардію, втому за фізичного навантаження або без нього, м’язову слабкість, міалгію, когнітивні порушення та ін.Симптоми постковідного синдрому поділяють на постійні та періодичні. У пацієнта може спостерігатись один або декілька симптомів одночасно. Пацієнти, які були госпіталізовані в інфекційні відділення лікувальних закладів для лікування гострої фази захворювання на COVID-19, мають більшу ймовірність тривалого перебігу захворювання та важкого постковідного синдрому у вигляді різноманітних патологічних проявів, що вказує на ураження багатьох систем та органів.На сучасному етапі фахівцю фармації потрібно добре знати і орієнтуватися не лише в основних симптомах та лікуванні гострої фази COVID-19, а й володіти знаннями щодо негативних наслідків даного захворювання для організму пацієнта у вигляді постковідного синдрому, методів діагностики, фармакотерапії та видів реабілітаційних заходів. Коронавірусна хвороба (COVID-19) та постковідні стани є важким мультисистемним вірусним захворюванням із важкими довготривалими наслідками для організму хворого, які пацієнт не завжди пов’язує з перенесеним захворюванням, і тому фахівці фармації як найдоступніші для населення медичні працівники мають володіти знаннями щодо основних симптомів, діагностики та лікування COVID-19 та постковідного синдрому для надання повноцінної та якісної фармацевтичної допомоги...
- Open Access
- 28 April 2025
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 2,p. 34-41
Analysis of medical oxygen providing of medical institutions in the western region of Ukraine during the pandemic of coronavirus disease (COVID-19)
During the COVID-19 pandemic, medical oxygen has become one of the main drugs in eliminating the decrease in oxygenation due to this disease. Changes and corrections in treatment protocols – dose adjustment, regulation and humidification of oxygen flow, appointment of oxygen therapy in various cases of difficulty breathing led to the acquisition of significant experience by doctors in the use of medical oxygen as a full-fledged component of pharmacotherapy of pulmonary pathology of patients who require additional oxygen. The purpose of the work was to determine the dynamics of medical oxygen consumption in some medical and preventive institutions of the Western region of Ukraine, taking into account the dynamics of COVID-19 prevalence indicators, and trends in the volumes of production and sales of medical oxygen according to the domestic manufacturer in the conditions of the coronavirus disease (COVID-19) pandemic. The object of the study was the incidence rates of COVID-19 in some regions of the Western region of Ukraine during the pandemic and the protocols for providing medical care for this disease. We also studied the dynamics of the production and sale of medical oxygen according to data from LLC Firma «Lvivkisen» in the studied regions for 2020–2022. The dynamics of medical oxygen consumption in Volyn, Zakarpattia, Ivano-Frankivsk, Lviv, Rivne, Khmelnytsky regions of the Western region of Ukraine in the period 2020–2022 was analyzed according to data from LLC Firma «Lvivkisen». It was found that there was an increase in oxygen consumption in the period 2020–2021, which is associated with a significant increase in patients with complicated forms of COVID-19 who required additional oxygenation due to lung damage by the SARS-CoV-2 virus (strains (B.1.1.7) «Alpha», «Beta» (B.1.351)), which are characterized by damage to lung tissue, therefore, the need for medical oxygen and the appropriate equipment of beds in medical institutions is increasing. It was found that since 2022, a decrease in medical oxygen consumption by medical institutions in the regions of the Western region of Ukraine has already been observed due to the dominance of the strain B.1.617.2 «Delta», which mainly affects the patient's upper respiratory tract, therefore, the need for oxygenation is lower, respectively, the need for medical oxygen supply has decreased. It has been studied that the increase in the consumption of medical oxygen correlates with the growth of COVID-19 incidence and the development of its complicated forms.
- 28 April 2025
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 2,p. 34-41
Open AccessAnalysis of medical oxygen providing of medical institutions in the western region of Ukraine during the pandemic of coronavirus disease (COVID-19)
During the COVID-19 pandemic, medical oxygen has become one of the main drugs in eliminating the decrease in oxygenation due to this disease. Changes and corrections in treatment protocols – dose adjustment, regulation and humidification of oxygen flow, appointment of oxygen therapy in various cases of difficulty breathing led to the acquisition of significant experience by doctors in the use of medical oxygen as a full-fledged component of pharmacotherapy of pulmonary pathology of patients who require additional oxygen. The purpose of the work was to determine the dynamics of medical oxygen consumption in some medical and preventive institutions of the Western region of Ukraine, taking into account the dynamics of COVID-19 prevalence indicators, and trends in the volumes of production and sales of medical oxygen according to the domestic manufacturer in the conditions of the coronavirus disease (COVID-19) pandemic. The object of the study was the incidence rates of COVID-19 in some regions of the Western region of Ukraine during the pandemic and the protocols for providing medical care for this disease. We also studied the dynamics of the production and sale of medical oxygen according to data from LLC Firma «Lvivkisen» in the studied regions for 2020–2022. The dynamics of medical oxygen consumption in Volyn, Zakarpattia, Ivano-Frankivsk, Lviv, Rivne, Khmelnytsky regions of the Western region of Ukraine in the period 2020–2022 was analyzed according to data from LLC Firma «Lvivkisen». It was found that there was an increase in oxygen consumption in the period 2020–2021, which is associated with a significant increase in patients with complicated forms of COVID-19 who required additional oxygenation due to lung damage by the SARS-CoV-2 virus (strains (B.1.1.7) «Alpha», «Beta» (B.1.351)), which are characterized by damage to lung tissue, therefore, the need for medical oxygen and the appropriate equipment of beds in medical institutions is increasing. It was found that since 2022, a decrease in medical oxygen consumption by medical institutions in the regions of the Western region of Ukraine has already been observed due to the dominance of the strain B.1.617.2 «Delta», which mainly affects the patient's upper respiratory tract, therefore, the need for oxygenation is lower, respectively, the need for medical oxygen supply has decreased. It has been studied that the increase in the consumption of medical oxygen correlates with the growth of COVID-19 incidence and the development of its complicated forms.
- Open Access
- 23 October 2023
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 106 (2) , 51-56
The study of the state of awareness of pharmaceutical workers regarding coronavirus disease (COVID-19)
Aim. To analyze and summarize the results of a questionnaire on the state of awareness of pharmaceutical workers in the Western regions of Ukraine about the coronavirus disease (COVID-19). Materials and methods. The results of a survey of pharmacy managers, pharmacists and interns working in pharmacies in 8 regions of the Western area of Ukraine were used. The survey of respondents lasted 12 months: December 2021 – December 2022. A special questionnaire was developed to determine the level of knowledge about the coronavirus disease (COVID-19) caused by the SARS-CoV-2 coronavirus. Results and discussion. With the beginning of the full-scale invasion of the Russian Federation, COVID-19 practically disappeared from the information space and ceased to be an urgent issue for Ukrainians. However, in recent weeks, the Ministry of Health has recorded an increase in the number of hospitalizations due to the coronavirus disease. During the period of martial law and the coronavirus disease pandemic (COVID-19), the pharmacy is the most accessible healthcare institution for the population and ranks first in terms of the number of citizens’ requests for symptoms, methods of treatment and prevention of SARS-CoV-2, therefore, the awareness of pharmacists – practitioners about COVID-19 is very important to provide complete and high-quality pharmaceutical care to patients. A review of the specialized scientific literature over the past 5 years confirmed the lack of studies on the level of awareness of pharmaceutical workers about the symptoms, methods of diagnosis, treatment and prevention of the main diseases that are widespread in the Western regions of Ukraine. With the help of a questionnaire, we conducted an expert assessment of the level of knowledge of pharmacy managers, pharmacists and interns working in pharmacy institutions in 8 regions of the Western area of Ukraine regarding the main symptoms, methods of diagnosis, treatment and prevention of uncomplicated forms of the coronavirus disease (COVID-19). After analyzing the answers of the respondents, it can be assumed that pharmaceutical workers know the main manifestations of the coronavirus disease (COVID-19) and are oriented towards the threatening indicators of the patient’s condition. It causes concern that some respondents incorrectly determine the reasons for prescribing antibacterial therapy to a patient, which can lead to incorrect recommendations and advice during the implementation of pharmaceutical care, however, the introduction of electronic prescriptions for dispensing antimicrobial drugs and information and educational work with pharmaceutical workers should correct the situation. Conclusions. In our opinion, it is promising to conduct further research to improve the level of knowledge and competencies of pharmaceutical workers during their specialization courses and thematic improvement in the system of continuous professional development
- 23 October 2023
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 106 (2) , 51-56
Open AccessThe study of the state of awareness of pharmaceutical workers regarding coronavirus disease (COVID-19)
Aim. To analyze and summarize the results of a questionnaire on the state of awareness of pharmaceutical workers in the Western regions of Ukraine about the coronavirus disease (COVID-19). Materials and methods. The results of a survey of pharmacy managers, pharmacists and interns working in pharmacies in 8 regions of the Western area of Ukraine were used. The survey of respondents lasted 12 months: December 2021 – December 2022. A special questionnaire was developed to determine the level of knowledge about the coronavirus disease (COVID-19) caused by the SARS-CoV-2 coronavirus. Results and discussion. With the beginning of the full-scale invasion of the Russian Federation, COVID-19 practically disappeared from the information space and ceased to be an urgent issue for Ukrainians. However, in recent weeks, the Ministry of Health has recorded an increase in the number of hospitalizations due to the coronavirus disease. During the period of martial law and the coronavirus disease pandemic (COVID-19), the pharmacy is the most accessible healthcare institution for the population and ranks first in terms of the number of citizens’ requests for symptoms, methods of treatment and prevention of SARS-CoV-2, therefore, the awareness of pharmacists – practitioners about COVID-19 is very important to provide complete and high-quality pharmaceutical care to patients. A review of the specialized scientific literature over the past 5 years confirmed the lack of studies on the level of awareness of pharmaceutical workers about the symptoms, methods of diagnosis, treatment and prevention of the main diseases that are widespread in the Western regions of Ukraine. With the help of a questionnaire, we conducted an expert assessment of the level of knowledge of pharmacy managers, pharmacists and interns working in pharmacy institutions in 8 regions of the Western area of Ukraine regarding the main symptoms, methods of diagnosis, treatment and prevention of uncomplicated forms of the coronavirus disease (COVID-19). After analyzing the answers of the respondents, it can be assumed that pharmaceutical workers know the main manifestations of the coronavirus disease (COVID-19) and are oriented towards the threatening indicators of the patient’s condition. It causes concern that some respondents incorrectly determine the reasons for prescribing antibacterial therapy to a patient, which can lead to incorrect recommendations and advice during the implementation of pharmaceutical care, however, the introduction of electronic prescriptions for dispensing antimicrobial drugs and information and educational work with pharmaceutical workers should correct the situation. Conclusions. In our opinion, it is promising to conduct further research to improve the level of knowledge and competencies of pharmaceutical workers during their specialization courses and thematic improvement in the system of continuous professional development
- Open Access
- 24 August 2023
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 14-26
Analysis of trends and necessity of extemporal compounding of medicinal forms in pharmacies during wartime and the COVID-19 pandemic in Ukraine
The need to saving of the pharmacies are preparing extemporaneous dosage forms (DF) is substantiated, and their effectiveness in the conditions of the coronavirus pandemic, martial law is shown. The purpose of work was to conduct an analysis of the dynamics of the pharmacy number that manufacture EDF on the example of the Lviv region, the city of Lviv during 30 years, in order to determine trends. It was to study the list of DFs that were extemporaneously compounded. The list of DFs was analyzed, with an emphasis on the list of disinfectant solutions for sanitizing hands during the COVID-19 pandemic and wartime. The analysis objects were documents, order books of pharmacies with production departments during 30 years of activity. The list of pharmaceuticals from 14 pharmacies that have valid licenses and actually carry out extemporaneous production in the city of Lviv, the Lviv region was studied. Research methods: historical, bibliographic, documentary, content analysis, systematization and generalization. We have selected a set of 11 dosage forms, which were most often compounded during the coronavirus pandemic and martial law during 2020-2023, these prescriptions can be recommended for implementation in the work of compounding departments of private pharmacies. It was found that most industrial disinfectant solutions contain 60% isopropyl alcohol or 70%‒75% ethyl alcohol, so these solutions do not meet WHO recommendations for disinfection during a pandemic COVID-19. It was established that the costs of disinfectant solutions per one litre were higher by 44.4% compared to one litre of extemporaneous production disinfectants, which has significant economic benefits for the rational use of budget funds. It was substantiated that the urgent task of harmonizing with the legislation of the European Union regarding the work of pharmacies that have extemporaneous production requires the introduction of changes to the Resolution of the CMU dated 30.11.2016 N 929 on Licensing conditions for conducting business activities in the production of medicinal products, wholesale and retail trade medicinal products, on the mandatory extemporaneous production of medicinal forms in each pharmacy, regardless of the form of ownership. It was established that 71.4% of extemporaneous pharmacies are communally owned, when chain pharmacies do not perform such a function at all, therefore it is necessary to harmonize with EU requirements for the presence of compounding departments in each pharmacy with good conditions and personnel for production. The need for a hospital pharmacy with appropriate staff in each hospital for the preparation of sterile and non-sterile medical forms in Ukraine, and to ensure the practice of students and the internship of pharmacists is substantiated.
- 24 August 2023
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 4,p. 14-26
Open AccessAnalysis of trends and necessity of extemporal compounding of medicinal forms in pharmacies during wartime and the COVID-19 pandemic in Ukraine
The need to saving of the pharmacies are preparing extemporaneous dosage forms (DF) is substantiated, and their effectiveness in the conditions of the coronavirus pandemic, martial law is shown. The purpose of work was to conduct an analysis of the dynamics of the pharmacy number that manufacture EDF on the example of the Lviv region, the city of Lviv during 30 years, in order to determine trends. It was to study the list of DFs that were extemporaneously compounded. The list of DFs was analyzed, with an emphasis on the list of disinfectant solutions for sanitizing hands during the COVID-19 pandemic and wartime. The analysis objects were documents, order books of pharmacies with production departments during 30 years of activity. The list of pharmaceuticals from 14 pharmacies that have valid licenses and actually carry out extemporaneous production in the city of Lviv, the Lviv region was studied. Research methods: historical, bibliographic, documentary, content analysis, systematization and generalization. We have selected a set of 11 dosage forms, which were most often compounded during the coronavirus pandemic and martial law during 2020-2023, these prescriptions can be recommended for implementation in the work of compounding departments of private pharmacies. It was found that most industrial disinfectant solutions contain 60% isopropyl alcohol or 70%‒75% ethyl alcohol, so these solutions do not meet WHO recommendations for disinfection during a pandemic COVID-19. It was established that the costs of disinfectant solutions per one litre were higher by 44.4% compared to one litre of extemporaneous production disinfectants, which has significant economic benefits for the rational use of budget funds. It was substantiated that the urgent task of harmonizing with the legislation of the European Union regarding the work of pharmacies that have extemporaneous production requires the introduction of changes to the Resolution of the CMU dated 30.11.2016 N 929 on Licensing conditions for conducting business activities in the production of medicinal products, wholesale and retail trade medicinal products, on the mandatory extemporaneous production of medicinal forms in each pharmacy, regardless of the form of ownership. It was established that 71.4% of extemporaneous pharmacies are communally owned, when chain pharmacies do not perform such a function at all, therefore it is necessary to harmonize with EU requirements for the presence of compounding departments in each pharmacy with good conditions and personnel for production. The need for a hospital pharmacy with appropriate staff in each hospital for the preparation of sterile and non-sterile medical forms in Ukraine, and to ensure the practice of students and the internship of pharmacists is substantiated.
- Open Access
- 29 October 2022
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 5,p. 3-11
Overview of the pharmaceutical market of anticoagulants for the treatment of coronavirus disease (COVID-19) during marital state in Ukraine
The war in Ukraine has not changed the epidemic situation with coronavirus disease (COVID-19). Further, new cases of disease and death among the population are recorded every day. A large number of people in shelters and bomb shelters, in transport during the evacuation, increases the risk of infection. One of the main complications that occur in patients with COVID-19 is the formation of blood clots, which can lead to negative consequences and death of the patient, and therefore, at the present stage, the use of anticoagulants in the form of low molecular weight heparins plays a very important role in the hospital treatment of coronavirus disease. Heparin potentially has advantages over other anticoagulants for its not only anticoagulant but also anti-inflammatory properties (reducing lung inflammation and improving oxygenation) and also has potential antiviral properties. The purpose of our study was to analyze the availability and range of anticoagulants used to treat coronavirus disease (COVID-19) and post-COVID syndrome in Ukraine. The materials of our study were the data of the State Register of Medicines, the Compendium directory, the Register of wholesale selling prices for medicines and the prices for anticoagulants in Lviv pharmacies. We have analyzed the domestic market of low molecular weight heparins used for the treatment of coronavirus disease (COVID-19) and post-covid syndrome according to the international non-proprietary name, taking into account all forms of production, manufacturers and prices. It has been established that in the pharmaceutical market of Ukraine these medicines are represented by 9 trade names, which in turn are divided according to the amount of active substance in 1 ml of solution. Analyzing the manufacturing companies, it was found that more than half (52.6%) of the presented heparins were produced in Ukraine, and 47.4% of the trade names of drugs are imported. The state of supply and prices for low molecular weight heparins in pharmacies in Lviv was analyzed. It has been established that the pharmacies of the city are provided with a sufficient amount of these medicines, manufacturers and dosages are widely represented. Although the current number of active patients coronavirus disease (COVID-19) in Ukraine has decreased compared to 2021, there is still a large number of patients who are treated with anticoagulants after an illness as a preventive measure or rehabilitation. There fore, the provision of pharmacies with a wide range of anticoagulant drugs in sufficient quantity and variety of dosage plays an important role in providing pharmaceutical assistance to the population in full.
- 29 October 2022
- Published by The State Expert Center of the Ministry of Health of Ukraine in Farmatsevtychnyi zhurnal
- No. 5,p. 3-11
Open AccessOverview of the pharmaceutical market of anticoagulants for the treatment of coronavirus disease (COVID-19) during marital state in Ukraine
The war in Ukraine has not changed the epidemic situation with coronavirus disease (COVID-19). Further, new cases of disease and death among the population are recorded every day. A large number of people in shelters and bomb shelters, in transport during the evacuation, increases the risk of infection. One of the main complications that occur in patients with COVID-19 is the formation of blood clots, which can lead to negative consequences and death of the patient, and therefore, at the present stage, the use of anticoagulants in the form of low molecular weight heparins plays a very important role in the hospital treatment of coronavirus disease. Heparin potentially has advantages over other anticoagulants for its not only anticoagulant but also anti-inflammatory properties (reducing lung inflammation and improving oxygenation) and also has potential antiviral properties. The purpose of our study was to analyze the availability and range of anticoagulants used to treat coronavirus disease (COVID-19) and post-COVID syndrome in Ukraine. The materials of our study were the data of the State Register of Medicines, the Compendium directory, the Register of wholesale selling prices for medicines and the prices for anticoagulants in Lviv pharmacies. We have analyzed the domestic market of low molecular weight heparins used for the treatment of coronavirus disease (COVID-19) and post-covid syndrome according to the international non-proprietary name, taking into account all forms of production, manufacturers and prices. It has been established that in the pharmaceutical market of Ukraine these medicines are represented by 9 trade names, which in turn are divided according to the amount of active substance in 1 ml of solution. Analyzing the manufacturing companies, it was found that more than half (52.6%) of the presented heparins were produced in Ukraine, and 47.4% of the trade names of drugs are imported. The state of supply and prices for low molecular weight heparins in pharmacies in Lviv was analyzed. It has been established that the pharmacies of the city are provided with a sufficient amount of these medicines, manufacturers and dosages are widely represented. Although the current number of active patients coronavirus disease (COVID-19) in Ukraine has decreased compared to 2021, there is still a large number of patients who are treated with anticoagulants after an illness as a preventive measure or rehabilitation. There fore, the provision of pharmacies with a wide range of anticoagulant drugs in sufficient quantity and variety of dosage plays an important role in providing pharmaceutical assistance to the population in full.
- Open Access
- 28 October 2022
- Published by Professional Event, LLC in Family medicine. European practices
- No. 3,p. 16-21
Research on the State of Awareness of Pharmaceutical Workers About Coronavirus Disease (COVID-19)
The article presents the results of a survey of 269 pharmaceutical workers to determine the level of knowledge of the etiology, pathogenesis, treatment and prevention of coronavirus disease (COVID-19) in order to provide complete and quality pharmaceutical care to patients. The objective: analysis and generalization of the results of the survey on the state of awareness of pharmaceutical workers in the western region of Ukraine about coronavirus disease (COVID-19). Materials and methods. The survey was conducted in Lviv among pharmacists-students of internship, specialization, thematic improvement and pharmacists-interns at the Department of Organization and Economics of Pharmacy, Drug Technology and Pharmacoeconomics Department of Management and Economy, Drug Technology and Pharmacoeconomics of Postgraduate Faculty Danylo Halytsky National Medical University. The first part of the questions concerned general information about the respondents. In the second part, respondents were asked questions about the main manifestations, threatening symptoms, surveillance measures, methods of treatment and prevention of uncomplicated coronavirus disease (COVID-19). Results. The results showed that pharmacists have theoretical knowledge about the pathogen, its routes of transmission, methods of diagnosis, treatment and prevention of uncomplicated forms of coronavirus disease (COVID-19), are guided by the threatening indicators of the patient, correctly determine the grounds for prescribing antibacterial drugs. Conclusions. Knowledge of the etiology, pathogenesis, treatment and prevention of the most common diseases and coronavirus disease (COVID-19) in particular plays an important role in the list of necessary competencies for the quality of professional development of a pharmaceutical worker.
- 28 October 2022
- Published by Professional Event, LLC in Family medicine. European practices
- No. 3,p. 16-21
Open AccessResearch on the State of Awareness of Pharmaceutical Workers About Coronavirus Disease (COVID-19)
The article presents the results of a survey of 269 pharmaceutical workers to determine the level of knowledge of the etiology, pathogenesis, treatment and prevention of coronavirus disease (COVID-19) in order to provide complete and quality pharmaceutical care to patients. The objective: analysis and generalization of the results of the survey on the state of awareness of pharmaceutical workers in the western region of Ukraine about coronavirus disease (COVID-19). Materials and methods. The survey was conducted in Lviv among pharmacists-students of internship, specialization, thematic improvement and pharmacists-interns at the Department of Organization and Economics of Pharmacy, Drug Technology and Pharmacoeconomics Department of Management and Economy, Drug Technology and Pharmacoeconomics of Postgraduate Faculty Danylo Halytsky National Medical University. The first part of the questions concerned general information about the respondents. In the second part, respondents were asked questions about the main manifestations, threatening symptoms, surveillance measures, methods of treatment and prevention of uncomplicated coronavirus disease (COVID-19). Results. The results showed that pharmacists have theoretical knowledge about the pathogen, its routes of transmission, methods of diagnosis, treatment and prevention of uncomplicated forms of coronavirus disease (COVID-19), are guided by the threatening indicators of the patient, correctly determine the grounds for prescribing antibacterial drugs. Conclusions. Knowledge of the etiology, pathogenesis, treatment and prevention of the most common diseases and coronavirus disease (COVID-19) in particular plays an important role in the list of necessary competencies for the quality of professional development of a pharmaceutical worker.